Nyheter
Triglycerider – de okända blodfetterna
De flesta känner till att ett högt kolesterolvärde inte är bra. Att det ökar risken för hjärt- och kärlsjukdomar. Inte lika många känner till att den andra typen av ”farliga” blodfetter – triglyceriderna – också behöver hållas i schack. På Lipigon ho...
Lipigon-CombiGene collaboration reaches milestone
The collaboration between Lipigon and CombiGene has reached a milestone. CombiGene announced today that a patent application has been filed. Read more in their press release (in Swedish). Combigene Press release
LIPIGON ENTERS LICENSING AND COLLABORATION AGREEMENT WITH COMBIGENE TO DEVELOP GENE THERAPY FOR LIPO
“We are very happy to enter this agreement with CombiGene ,” says Stefan K Nilsson, CEO at Lipigon. “Through the development of their epilepsy project, CombiGene has demonstrated a fantastic ability to handle the complexities of gene therapy. With ou...
LIPIGON HAS BEEN NOMINATED AS UNIVERSITY SPIN-OUT OF THE YEAR
Lipigon is nominated as this year’s spin-out company at UmeåGalan2017. As 1 of 3 nominees Lipigon has the chance to win the prestigious price November 9th. “The nomination as such is very honoring. It is another hallmark and confirmation of that we a...
LIPIGON CEO STEFAN K. NILSSON IN INTERVIEW AS INVITED SPEAKER FOR BIOFIT 2016
Lipigon CEO Stefan K. Nilsson is an invited speaker at BioFIT 2016 in Lille, France November 30th-December 1st. Dr. Nilsson will speak at the session “Are universities a short-term or long-term partner for spin offs?”. Bio-FIT is a leading partnering...
MIKAEL ELOFSSON INTERVIEWED AT ADD 2016
Lipigon board member Prof. Mikael Elofsson presented a screening-based approach to identify small molecules that stabilize and activate lipoprotein lipase, the key enzyme in lipid metabolism, at the Academic Drug Discovery meeting in Cambridge, UK. ...
AVAILABLE POSITIONS
Lipigon is expanding and looking for new talents to join our team. We are looking for; Project manager/laboratory manager with work experience from pharmaceutical industry and QC/validation. Laboratory assistants with experience from in vitro and...
LIPIGON AWARDED CONNECT´S PITCH PRIZE
Lipigon awarded Connect´s pitch prize at Biotech Umeå investment Day at Grand Hôtel Stockholm.
LIPIGON PATENT APPLICATION PUBLISHED
Lipigon’s first patent application “New plasma lipid lowering agents” were published today as #WO 2015/187082.
LIPIGON SCIENTISTS PUBLISH IN PRESTIGIOUS JOURNAL
Lipigon scientists publish SAR relationship in Eur J Med Chem. For further reading; Structure-activity relationships for lipoprotein lipase agonists that lower plasma triglycerides in vivo, Caraballo et al.
LIPIGON CEO TO FRONT NATIONAL SSMF CAMPAIGN
CEO Stefan K Nilsson is one of out of five promising young scientists that has been selected to front the Swedish Society for Medical Research’s fund raising campaign. The advertisements can been seen in national newspapers and magazine during the sp...
LIPIGON CEO STEFAN K NILSSON RECEIVES SSMF POSTDOCTORAL AWARD
Lipigon CEO Dr. Stefan K Nilsson has been awarded the Swedish Society for Medical Research postdoctoral support. Read more about the award here, in Swedish.
LIPIGON SCIENTISTS IDENTIFIES LPL ACTIVATORS
Lipigon scientists publish results for first LPL activators in Biochem Biophys Res Commun. For further reading; Identification of a small molecule that stabilizes lipoprotein lipase in vitro and lowers triglycerides in vivo, Larsson et al.
LIPIGON ATTENDS: BIOTECH UMEÅ INVESTMENT DAY
Lipigon attends: Biotech Umeå investment Day at Grand Hotel Stockholm to tuesday 27/1-2015.
Nyheter
Lipigons vd Stefan K. Nilsson ökar sitt innehav i bolaget
Lipigon Pharmaceuticals AB ("Lipigon") meddelar i dag att vd Stefan K. Nilsson har köpt aktier i Lip...
Lipigon publicerar delårsrapport för januari-september 2022
Lipigon Pharmaceuticals AB ("Lipigon") publicerar i dag sin delårsrapport för perioden 1 januari-30 ...
Umeå på börsen
Lipigon Pharmaceuticals AB ("Lipigon") anordnar tillsammans med andra börsnoterade bolag från Umeå e...